<DOC>
	<DOCNO>NCT00829283</DOCNO>
	<brief_summary>This control study test effectiveness stepped-care approach standard behavioral weight loss treatment obese patient Binge Eating Disorder ( BED ) . The major question whether stepped-care approach , begin behavioral weight loss follow decision tree additional intervention base early treatment response superior standard behavioral treatment .</brief_summary>
	<brief_title>Treatment Obesity Binge Eating : Behavioral Weight Loss Versus Stepped Care</brief_title>
	<detailed_description>The stepped-care arm study include obesity medication intervention . At start study , active medication sibutramine compare placebo control . On 10/8/2010 , Abbott Laboratories withdraw obesity drug sibutramine ( Meridia ) market light clinical trial data point increase risk stroke myocardial infarction . In response event , investigator submit IRB amendment change active obesity medication sibutramine Orlistat . The IRB amendment approve 11/4/2010 . The PI receive approval NIH/NIDDK Program Officer Robert Kuczmarski enact change .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Inclusion criterion : Obese ( BMI &gt; =30 ) Exclusion criterion : Medication regimen represent medical contraindication sibutramine Serious unstable uncontrolled medical condition represent contraindication sibutramine Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Experimental</keyword>
	<keyword>Comparator</keyword>
</DOC>